By mid-December 2012, sunscreen products on store shelves in the United States must meet stricter labeling regulations. Dr. Wang answers key questions on this topic.
In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.
The US Food and Drug Administration announced in late March that the drug ipilimumab (Yervoy™) had been approved for the treatment of patients with metastatic melanoma.
A multicenter study led by Memorial Sloan-Kettering Cancer Center investigators concluded that treatment with a new targeted therapy called PLX4032 resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.
The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
